Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
8 studies found for:    IL7R
Show Display Options
Rank Status Study
1 Recruiting IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells, Peripheral Blood Monocytes or Differentiated Macrophages of Rheumatoid Arthritis Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA
Condition: Rheumatoid Arthritis
Intervention: Other: Lab Work
2 Completed Single Ascending Doses Study of Anti- Interleukin-7 Receptor α Monoclonal Antibody (GSK2618960) in Healthy Volunteers
Condition: Autoimmune Diseases
Interventions: Drug: GSK2618960;   Drug: Placebo
3 Completed IL-7 Receptor Polymorphisms and Immune Recovery With HAART
Condition: HIV Infections
Intervention:
4 Recruiting Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis.
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Genetic: Polymorphism of Interleukins, Glypican, and Human Leukocyte Antigen Genes.
5 Terminated A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Part A: 100 mg/mL GSK2618960;   Drug: Part A: matching placebo;   Drug: Part B: Dose of GSK2618960 decided from Part A;   Drug: Part B: matching placebo;   Drug: Part C: Dose of GSK2618960 decided from Part A and B
6 Terminated A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Interventions: Biological: PF-06342674 0.25 mg/kg;   Biological: Placebo;   Biological: PF-06342674 1.5 mg/kg;   Biological: PF-06342674 6.0 mg/kg
7 Recruiting Genetic Basis of Primary Immunodeficiencies
Condition: Immunologic Deficiency Syndrome
Intervention:
8 Unknown  Effects of High Cut-off (HCO) Hemodialysis on Central Memory CD4+ T and Treg Cells in Patients With End-stage Kidney Disease
Conditions: End-stage Kidney Disease;   CD4 T Cells;   Central Memory T Cells;   Regulatory T Cells;   Uremic Toxins
Intervention: Device: Polyamide HD membrane

Indicates status has not been verified in more than two years